10.1002/mc.22878 Mol
DOI:10.1111/j.1467-2494.2005.00235.x [ Links ] 22
Disclosures: Robin Kate Kelley: Astra Zeneca: Grant/Research Support, Bayer: Grant/Research Support, Eli Lilly: Grant/Research Support, Exelixis: Grant/Research Support, Genentech/Roche: Grant/Research Support, Kinnate: Consultant, Merck: Grant/Research Support, Partner Therapeutics: Grant/Research Support, Regeneron: Consultant, Agios: Grant/Research Support, BMS: Grant/Research Support, QED: Grant/Research Support, Tyra: Grant/Research Support, Taiho: Grant/Research Support, Surface: Grant/Research Support, Servier: Grant/Research Support, GSK: Consultant, moderna: Consultant, J Pharma Inc.: Consultant, Relay Therapeutics: Grant/Research Support, Young Lee: AstraZeneca PLC: Employee, AstraZeneca PLC: Stock - publicly traded company, James Conway: Nothing to Disclose, John Kurland: Nothing to Disclose, Alejandra Negro: Nothing to Disclose, Patricia McCoon: AstraZeneca: Employee 1832 EMERALD-Y90: A PHASE 2 STUDY TO EVALUATE TRANSARTERIAL RADIOEMBOLIZATION (TARE) FOLLOWED BY DURVALUMAB (D) AND BEVACIZUMAB (B) FOR THE TREATMENT OF PARTICIPANTS (PTS) WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC) ELIGIBLE FOR EMBOLIZATION Riad Salem 1 Anne Noonan 2 Ben Spieler 3 Sarah White 4 Laura Kulik 5 Dex Underwood 6 Eric Heilbron 6 Binh Nguyen 6 Graham Wetherill 7 Renuka Iyer 8 , 1 Northwestern University, Chicago, IL, USA, 2 The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA, 3 University of Miami, Miami, FL, USA, 4 Medical College of Wisconsin, Milwaukee, WI, USA, 5 Northwestern Memorial Hospital, Chicago, IL, USA, 6 AstraZeneca, Gaithersburg, MD, USA, 7 AstraZeneca, Cambridge, UK, 8 Roswell Park Cancer Institute, Buffalo, NY, USA Background: Intermediate HCC is often treated with locoregional therapy (LRT), such as transarterial chemoembolization (TACE) or TARE
The Bioavailability Factor Standard alpha lipoic acid has a major hurdle: it is not very bioavailable
